Navigation Links
GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
Date:10/8/2007

- Innovative approach to developing anti-infective medicines provides hope

for combating problems of resistance -

PALO ALTO, Calif. and LONDON, Oct. 8 /PRNewswire/ -- Anacor Pharmaceuticals and GlaxoSmithKline today announced that they have entered into a worldwide strategic alliance for the discovery, development and commercialization of novel medicines for viral and bacterial diseases. The collaboration provides GlaxoSmithKline access to Anacor's proprietary boron-based chemistry for use against selected targets.

GlaxoSmithKline will participate in the alliance through its Infectious Diseases Centre of Excellence for Drug Discovery (ID CEDD). Under the terms of the agreement, Anacor will grant GlaxoSmithKline options to select product candidates developed under the collaboration that are directed to up to four discovery targets and with the potential for at least eight product options. Anacor will primarily be responsible for the discovery and development of boron-containing small molecule drug candidates through clinical proof of concept, at which point GlaxoSmithKline will have an exclusive option to license each compound for further development and commercialization on a worldwide basis. Anacor will have the right to further develop and commercialize compounds for which GlaxoSmithKline does not exercise its option. Anacor will receive a $12 million upfront payment and a $10 million equity financing commitment from GlaxoSmithKline. Contingent on achieving certain milestones, Anacor is eligible to receive discovery, development, regulatory and commercial milestones ranging up to $252 million and $331 million for each product candidate. If GlaxoSmithKline exercises its option at the proof of concept stage, Anacor will receive tiered double digit royalties, which are dependent on sales achieved.

Boron has been a relatively underutilized element in pharmaceutical products, in part due to a lack of naturally occurring boron
'/>"/>

SOURCE Anacor Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GenTel acquires GlaxoSmithKline chip platform
2. Deltanoid Pharmaceuticals begins phase II osteoporosis study
3. The Coming of Biotech Generic Pharmaceuticals
4. Biomedical Alliance about more than stem cells
5. Doyle seeks $2.5M for biomedical alliance
6. Alliance looks to create the right chemistry in SE Wisconsin
7. Biomedical alliance marks first full year
8. New alliance to provide Wi-Fi network for City of Madison
9. Budget axe could cut SE Wisconsin tech alliance funding
10. Biotech Alliance pushes ahead in SE Wisconsin with likely state funding
11. Milwaukee research alliance sees need for incubator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
(Date:12/22/2014)... Brussels (PRWEB) December 22, 2014 The ... the global leader of technical training across the life ... Clinical Data Management (SCDM) to provide the organization's ... certification programs —providing access to the more than 350 ... SCDM members with 10% off when registering for a ...
(Date:12/22/2014)... Calif. , Dec. 22, 2014  ( www.competitivehealth.com ... CoPatient, an online medical bill review and advocacy service, ... in the FREE WellCard Savings discount health services marketplace. ... bill that was more than they expected to pay. ... reduce health care costs, WellCard Savings is pleased to ...
(Date:12/19/2014)... 19, 2014 Charm Sciences is pleased ... the Detection of Aflatoxin M1 in raw commingled milk ... third party validation. The peer reviewed report of the ... Institute for Agricultural and Fisheries Research (ILVO-T&V) has been ... Aflatoxin B1, the most toxic aflatoxin and a known ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... materials result in longer-lasting, safer batteries for ... ... U.S. Department of Energy,s,(DOE) Argonne National Laboratory and Toda Kogyo ... the commercial production and,sales of Argonne,s patented composite cathode materials ...
... Switzerland and FAIRFIELD, New Jersey, March 13, "The ... uniquely positioned as the only biopharma company that,manufactures ... and,nasal delivery systems to administer the peptides. Since ... Laboratories, "Fortical" has,captured a near dominant 49% market ...
... CALGARY, March 13 /PRNewswire-FirstCall/ - SemBioSys Genetics ... portfolio of therapeutic,proteins for metabolic and cardiovascular ... European patent EP0986309(B1) entitled "Uses of Oil,Bodies". ... which has exclusively,licensed commercial rights associated with ...
Cached Biology Technology:Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 2Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 3Stonegate Report About Unigene Laboratories Inc. 2Stonegate Report About Unigene Laboratories Inc. 3Stonegate Report About Unigene Laboratories Inc. 4Stonegate Report About Unigene Laboratories Inc. 5Stonegate Report About Unigene Laboratories Inc. 6Stonegate Report About Unigene Laboratories Inc. 7Stonegate Report About Unigene Laboratories Inc. 8Stonegate Report About Unigene Laboratories Inc. 9Stonegate Report About Unigene Laboratories Inc. 10SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office 2SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office 3
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... By identifying a protein that acts as a genetic modifier, ... mystery of why some infants are born with a grave ... skin and limbs, while other infants bearing the same predisposing ... called EEC. EEC stands for "Ectodactyly, Ectodermal dysplasia, Clefting ...
... 2013: Data presented at EULAR 2013, the Annual Congress ... antibody biomarkers could significantly improve diagnosis in rheumatoid arthritis ... UH-RA.14 and UH-RA.21 were investigated; as a group ... in both early and seronegative disease, with 36% ...
... Xu, assistant professor of biomedical engineering at Tufts ... Scholar in Biomedical Sciences by the Pew Charitable ... past winners have included Nobel Prize winners, MacArthur ... Medical Research Award, identifies talented researchers in medicine ...
Cached Biology News:CSHL geneticists solve mystery of EEC Syndrome's variable severity in children 2CSHL geneticists solve mystery of EEC Syndrome's variable severity in children 3Tufts Engineer Qiaobing Xu named 2013 Pew Scholar 2
... Fully adjustable mixing angle, Variable speed, Digital ... a number of different sized tubes, Spillage ... cultures, keeping biological samples in suspension and ... be used in incubators up to 60C ...
...
... real-time PCR detection system uses a fixed ... nm) and two photomultiplier tubes for 2-color ... 2 system is built on an DNA ... gradient feature. This item includes the thermal ...
... is used to screen blots of mini format ... screen up to 40 different antibodies or sera ... The apparatus includes a base plate, 2 separate, ... 8 x 7 cm membranes, and gaskets and ...
Biology Products: